Pharmocann Global Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Pharmocann Global has been growing earnings at an average annual rate of 15.6%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 9.1% per year.
Wichtige Informationen
15.6%
Wachstumsrate der Gewinne
40.5%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 35.1% |
| Wachstumsrate der Einnahmen | -9.1% |
| Eigenkapitalrendite | -4,587.4% |
| Netto-Marge | -76.1% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
The Returns On Capital At Pharmocann Global (TLV:PMCN) Don't Inspire Confidence
Mar 30
Should You Use Pharmocann Global's (TLV:PMCN) Statutory Earnings To Analyse It?
Feb 04Pharmocann Global Ltd (TLV:PMCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Dec 31
The Returns At Pharmocann Global (TLV:PMCN) Provide Us With Signs Of What's To Come
Nov 26Aufschlüsselung der Einnahmen und Ausgaben
Wie Pharmocann Global Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 13 | -10 | 8 | 0 |
| 31 Mar 24 | 14 | -10 | 8 | 0 |
| 31 Dec 23 | 14 | -10 | 8 | 0 |
| 30 Sep 23 | 11 | -12 | 6 | 0 |
| 30 Jun 23 | 12 | -18 | 7 | 1 |
| 31 Mar 23 | 17 | -24 | 10 | 1 |
| 31 Dec 22 | 23 | -25 | 13 | 1 |
| 30 Sep 22 | 24 | -23 | 12 | 1 |
| 30 Jun 22 | 25 | -20 | 13 | 1 |
| 31 Mar 22 | 28 | -16 | 15 | 1 |
| 31 Dec 21 | 29 | -19 | 15 | 1 |
| 30 Sep 21 | 31 | -14 | 15 | 1 |
| 30 Jun 21 | 32 | -7 | 15 | 1 |
| 31 Mar 21 | 31 | 2 | 13 | 1 |
| 31 Dec 20 | 28 | 4 | 13 | 1 |
| 30 Sep 20 | 26 | 6 | 11 | 1 |
| 30 Jun 20 | 26 | 5 | 10 | 1 |
| 31 Mar 20 | 21 | -25 | 9 | 1 |
| 31 Dec 19 | 21 | -46 | 6 | 1 |
| 30 Sep 19 | 18 | -46 | 6 | 0 |
| 30 Jun 19 | 17 | -46 | 4 | 0 |
| 31 Mar 19 | 16 | -20 | 4 | 0 |
| 31 Dec 18 | 15 | 6 | 3 | 0 |
| 31 Dec 17 | 12 | 2 | 3 | 0 |
| 31 Dec 16 | 9 | 1 | 2 | 0 |
Qualität der Erträge: PMCN-M is currently unprofitable.
Wachsende Gewinnspanne: PMCN-M is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: PMCN-M is unprofitable, but has reduced losses over the past 5 years at a rate of 15.6% per year.
Beschleunigtes Wachstum: Unable to compare PMCN-M's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: PMCN-M is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.1%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: PMCN-M has a negative Return on Equity (-4587.44%), as it is currently unprofitable.